Trinity Financial Advisors LLC increased its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,404 shares of the company’s stock after buying an additional 81 shares during the period. Johnson & Johnson accounts for 0.4% of Trinity Financial Advisors LLC’s portfolio, making the stock its 25th largest position. Trinity Financial Advisors LLC’s holdings in Johnson & Johnson were worth $683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC lifted its position in Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares during the period. Norges Bank bought a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $4,609,399,000. Morgan Stanley grew its position in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Nordwand Advisors LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $785,273,000. Finally, Price T Rowe Associates Inc. MD grew its position in Johnson & Johnson by 15.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after purchasing an additional 3,849,148 shares during the last quarter. 67.57% of the stock is owned by institutional investors.
Johnson & Johnson Trading Down 0.2 %
Shares of JNJ stock opened at $163.87 on Thursday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The firm has a fifty day moving average price of $160.72 and a 200-day moving average price of $163.68. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. The company has a market cap of $425.85 billion, a price-to-earnings ratio of 34.28, a PEG ratio of 2.80 and a beta of 0.54.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd were issued a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 2.90%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend was Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is currently 99.58%.
Analyst Ratings Changes
Several brokerages recently commented on JNJ. UBS Group began coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective on the stock. Guggenheim began coverage on Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price for the company. Morgan Stanley lifted their target price on Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, May 19th. Finally, Citigroup assumed coverage on Johnson & Johnson in a report on Tuesday, May 30th. They issued a “buy” rating and a $185.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $171.57.
Insider Buying and Selling
In related news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is currently owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free research report on Johnson & Johnson from StockNews.com
- Smartsheet Investors’ Hasty Exit Can Be Your Gain
- Agilent Technologies Stock: Ready to Rise off the Floor
- Oilfield Services Growing Faster Than Wider Energy Sector
- La-Z-Boy Reclines To The Buy Zone As Industry Normalizes
- Five stocks we like better than Johnson & Johnson
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
